Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

miRNAs and Long-term Breast Cancer Survival: Evidence from the WHEL Study.

Natarajan L, Pu M, Davies SR, Vickery TL, Nelson SH, Pittman E, Parker BA, Ellis MJ, Flatt SW, Mardis ER, Marinac CR, Pierce JP, Messer K.

Cancer Epidemiol Biomarkers Prev. 2019 Sep;28(9):1525-1533. doi: 10.1158/1055-9965.EPI-18-1322. Epub 2019 Jun 11.

PMID:
31186261
2.

Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.

Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Sveli MAT, Kyte JA, Kristensen VN, Geitvik GA, Schlichting E, Wist EA, Sørlie T, Russnes HG, Naume B.

Breast Cancer Res. 2017 Nov 14;19(1):120. doi: 10.1186/s13058-017-0911-9.

3.

Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.

Krishnan P, Ghosh S, Wang B, Li D, Narasimhan A, Berendt R, Graham K, Mackey JR, Kovalchuk O, Damaraju S.

BMC Genomics. 2015 Sep 29;16:735. doi: 10.1186/s12864-015-1899-0.

4.

Research-based PAM50 signature and long-term breast cancer survival.

Pu M, Messer K, Davies SR, Vickery TL, Pittman E, Parker BA, Ellis MJ, Flatt SW, Marinac CR, Nelson SH, Mardis ER, Pierce JP, Natarajan L.

Breast Cancer Res Treat. 2019 Sep 21. doi: 10.1007/s10549-019-05446-y. [Epub ahead of print]

PMID:
31542876
5.

A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.

Inamoto T, Uehara H, Akao Y, Ibuki N, Komura K, Takahara K, Takai T, Uchimoto T, Saito K, Tanda N, Yoshikawa Y, Minami K, Hirano H, Nomi H, Kato R, Hayashi T, Azuma H.

Dis Markers. 2018 Jun 20;2018:5468672. doi: 10.1155/2018/5468672. eCollection 2018.

6.

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.

Martin M, Brase JC, Ruiz A, Prat A, Kronenwett R, Calvo L, Petry C, Bernard PS, Ruiz-Borrego M, Weber KE, Rodriguez CA, Alvarez IM, Segui MA, Perou CM, Casas M, Carrasco E, Caballero R, Rodriguez-Lescure A.

Breast Cancer Res Treat. 2016 Feb;156(1):81-9. doi: 10.1007/s10549-016-3725-z. Epub 2016 Feb 24.

7.

Meta-microRNA Biomarker Signatures to Classify Breast Cancer Subtypes.

Oztemur Islakoglu Y, Noyan S, Aydos A, Gur Dedeoglu B.

OMICS. 2018 Nov;22(11):709-716. doi: 10.1089/omi.2018.0157. Epub 2018 Nov 2.

PMID:
30388053
8.

Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer.

Zhang Y, Sui J, Shen X, Li C, Yao W, Hong W, Peng H, Pu Y, Yin L, Liang G.

Oncol Rep. 2017 Jun;37(6):3543-3553. doi: 10.3892/or.2017.5612. Epub 2017 Apr 28.

PMID:
28498428
9.

The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.

Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, Müller-Holzner E, Singer CF, Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C, Ferree S, Liu S, Cowens JW, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2014 Mar 1;20(5):1298-305. doi: 10.1158/1078-0432.CCR-13-1845. Epub 2014 Feb 11.

10.

Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process.

Khodadadi-Jamayran A, Akgol-Oksuz B, Afanasyeva Y, Heguy A, Thompson M, Ray K, Giro-Perafita A, Sánchez I, Wu X, Tripathy D, Zeleniuch-Jacquotte A, Tsirigos A, Esteva FJ.

Oncotarget. 2018 Feb 5;9(16):12868-12878. doi: 10.18632/oncotarget.24403. eCollection 2018 Feb 27.

11.

Novel prognostic and predictive microRNA targets for triple-negative breast cancer.

Turashvili G, Lightbody ED, Tyryshkin K, SenGupta SK, Elliott BE, Madarnas Y, Ghaffari A, Day A, Nicol CJB.

FASEB J. 2018 May 29:fj201800120R. doi: 10.1096/fj.201800120R. [Epub ahead of print]

PMID:
29812973
12.

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).

Liu MC, Pitcher BN, Mardis ER, Davies SR, Friedman PN, Snider JE, Vickery TL, Reed JP, DeSchryver K, Singh B, Gradishar WJ, Perez EA, Martino S, Citron ML, Norton L, Winer EP, Hudis CA, Carey LA, Bernard PS, Nielsen TO, Perou CM, Ellis MJ, Barry WT.

NPJ Breast Cancer. 2016;2. pii: 15023. doi: 10.1038/npjbcancer.2015.23. Epub 2016 Jan 6.

13.

Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.

Liu Y, Cai Q, Bao PP, Su Y, Cai H, Wu J, Ye F, Guo X, Zheng W, Zheng Y, Shu XO.

Breast Cancer Res Treat. 2015 Jul;152(1):183-191. doi: 10.1007/s10549-015-3460-x. Epub 2015 Jun 11.

14.

Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence.

Sueta A, Yamamoto Y, Tomiguchi M, Takeshita T, Yamamoto-Ibusuki M, Iwase H.

Oncotarget. 2017 Jul 22;8(41):69934-69944. doi: 10.18632/oncotarget.19482. eCollection 2017 Sep 19.

15.

miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients.

Lánczky A, Nagy Á, Bottai G, Munkácsy G, Szabó A, Santarpia L, Győrffy B.

Breast Cancer Res Treat. 2016 Dec;160(3):439-446. doi: 10.1007/s10549-016-4013-7. Epub 2016 Oct 15.

PMID:
27744485
16.

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.

Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu S, Leung S, Geiss G, Snider J, Vickery T, Davies SR, Mardis ER, Gnant M, Sestak I, Ellis MJ, Perou CM, Bernard PS, Parker JS.

BMC Med Genomics. 2015 Aug 22;8:54. doi: 10.1186/s12920-015-0129-6.

17.

A 4-microRNA signature predicts lymph node metastasis and prognosis in breast cancer.

Chen X, Wang YW, Zhu WJ, Li Y, Liu L, Yin G, Gao P.

Hum Pathol. 2018 Jun;76:122-132. doi: 10.1016/j.humpath.2018.03.010. Epub 2018 Mar 17.

PMID:
29555574
18.

Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse.

Falato C, Tobin NP, Lorent J, Lindström LS, Bergh J, Foukakis T.

Mol Oncol. 2016 Apr;10(4):517-25. doi: 10.1016/j.molonc.2015.11.004. Epub 2015 Nov 18.

19.

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.

Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, Greil R, Dubsky P, Stoeger H, Rudas M, Jakesz R, Ferree S, Cowens JW, Nielsen T, Schaper C, Fesl C, Cuzick J.

Ann Oncol. 2015 Aug;26(8):1685-91. doi: 10.1093/annonc/mdv215. Epub 2015 May 1.

PMID:
25935792
20.

Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c.

Nygren MK, Tekle C, Ingebrigtsen VA, Mäkelä R, Krohn M, Aure MR, Nunes-Xavier CE, Perälä M, Tramm T, Alsner J, Overgaard J, Nesland JM, Borgen E, Børresen-Dale AL, Fodstad Ø, Sahlberg KK, Leivonen SK.

Br J Cancer. 2014 Apr 15;110(8):2072-80. doi: 10.1038/bjc.2014.113. Epub 2014 Feb 27.

Supplemental Content

Support Center